Medical Marijuana Market, By Application (Pain Management (Neuropathic ,Inflammatory), Neurological Health Management (Sclerosis ,Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Other Diseases), Mental Health Management ( Post Traumatic Stress Disorder (PTSD), Depression, Anxiety, ADHD, Others) ,Others); By Distribution Channel (Pharmacies, Hospitals and Dispensaries, Online Retailers); By Type (Indica, Sativa, Hybrid); By Form (Capsule, Spray, Oil, Others) ; By Region (U.S., Canada, Mexico, Rest of North America, UK, France, Germany, Italy, Benelux Union, Nordic Countries and Rest of Europe, New Zealand, Australia, South Korea, Southeast Asia , Rest of Asia Pacific , Brazil, Argentina, Uruguay, Rest of Latin America, Israel, Zimbabwe, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
The growth of medicine and pharmaceuticals over the last century has been a fascination for humankind. With the advancement in medicines and higher investment being poured into the development of medicines that are more economic than its predecessors, the lower strata of the society are now being opened to quality healthcare in countries such as Denmark and Sweden. However, the cost of production remains comparatively higher and the side effects of medicinal tablets and syrups are still a point of contention among the experts. The alternatives to such synthesized medicines are ongoing, and the naturally occurring cannabis plant has strong advocates in the Western world. Medical Cannabis, also called Medical Marijuana (MMJ), are those types of cannabis strains that can be used for medicinal purposes after being approved by the government agencies. The global medical marijuana market is seeing increasing growth in several countries in Europe and Canada as a result of the relaxation of government restrictions for the production of cannabis medicines. Although rigorous testing and standardization consensus hasn't been reached yet among the international community, initial lab test findings suggest that the use of cannabis can reduce the effects caused due to chemotherapy and HIV/AIDS. It also has the potential to cure chronic pain, muscle spasms and various forms of epilepsy. Research on whether medical cannabis can reduce the impact of COVID-19 by boosting the immune system is being conducted by several organizations. In the U.S. state of Florida, around 630 retail licenses for medical cannabis had been issued until 2019.
The global medical marijuana market was estimated to be valued at US$ 16.86 Bn in 2018 and is expected to grow at a CAGR of 20.55% during the forecast period.
Type Outlook:
Based on the type of cannabis used, the global medical marijuana market is segmented into sativas, indicas and hybrid. The strains have been developed by cannabis growers across different continents. The Indica strain contains higher CBD (Cannabidiol) content and a lower THC (delta-9-tetrahydrocannabinol) content, while sativa strain contains higher THC and lower CBD. Indica strains are thus suited for providing mental relaxation, reduced nausea, bringing down acute pains, increase in appetite, amongst other uses. Sativa, on the other hand, is used for treating anxiety, depression, chronic pain, amongst others. It is commonly used as a day-time medicine. Hybrids are those strains that show properties in between that of sativa and indica strain. Canopy Growth Corporation, for example, is a medical marijuana manufacturer that brings out cannabis oil products that have a different THC and CBD ratio, depending on the customer's needs.
Application Outlook:
Based on the application, the global medical marijuana market can be broadly segmented into pain management, neurological health management, mental health management, and others. Medical experts suggest that cannabis plant oil can be used for autoimmune diseases as immunotherapy, reducing psychotic symptoms in schizophrenia and even as a rehabilitation drug for those who are undergoing heroin addiction treatments. Stronger shreds of evidence persuade experts to believe that cannabis can also be used for the reduction of seizure in patients. In many states in the U.S. such as Ohio and California, medical physicians are legally permitted to prescribe cannabis to their patients. With newer cross-breeding being tried out to treat dangerous illnesses such as Parkinson's and Alzheimer’s disease, the global medical marijuana industries are showing signs of promise in countries such as the U.S.
Region Outlook:
Based on the regions, North America accounted for the highest share in the global medical marijuana market in 2018, as a result of liberal marijuana laws in several U.S. states, Canada and Mexico. Canada passed the Cannabis Act in 2018, which made it the first developed country to legalize marijuana consumption among the adult population. Medical marijuana has now been legalized in over 30 countries around the globe. The Netherlands, Poland, and Italy are some of the countries in Europe that have permitted the use of marijuana for medical purposes. Europe is a key export market for Canada, i.e. it is legally allowed to export marijuana. The increasing awareness among the end-users regarding some of the proclaimed benefits of marijuana with reduced side effects is expected to propel the growth of the global medical marijuana market.
Medical Marijuana Market Revenue & Forecast, (US$ Billion), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of medical marijuana market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the medical marijuana market are Abattis Bioceuticals Corp., Agripharm Corp., Aurora Cannabis Enterprises Inc.,Cannabis Sativa, Inc., CannaGrow Holdings, Inc., Canopy Growth Corporation, Cara Therapeutics, Inc, Cresco Labs, LLC, Emerald Health Botanicals Inc. , Growblox Sciences, Inc., GW Pharmaceuticals plc, Insys Therapeutics, Inc. , Lexaria Corp., Medical Marijuana Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceuticals USA, Inc.,Tweed Inc.,United Cannabis Corporation,Whistler Medical Marijuana Corp , amongst others.
Medical Marijuana Market:
- By Application
- Pain Management
- Neuropathic
- Inflammatory
- Neurological Health Management
- Sclerosis
- Epilepsy
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- Other Diseases
- Mental Health Management
- Post Traumatic Stress Disorder (PTSD)
- Depression
- Anxiety
- ADHD
- Others
- Others
- Pain Management
- By Distribution Channel
- Pharmacies
- Hospitals and Dispensaries
- Online Retailers
- By Type
- Indica
- Sativa
- Hybrid
- By Form
- Capsule
- Spray
- Oil
- Others
- By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2017
1.2.2. Base Year: 2018
1.2.3. Forecast Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Medical Marijuana Market
6. Market Synopsis:
Medical Marijuana Market
7. Medical Marijuana
Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Medical Marijuana Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Medical Marijuana Market
7.6. Porter’s Five Force Analysis
8. Global Medical Marijuana Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global Medical Marijuana Market Revenue (US$ Mn)
8.2. Global Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Application
8.2.1. Pain Management (Definition, Market
Estimation and Penetration, 2015 – 2018, Market Estimation (2015 – 2018),
Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Neurological Health Management, Inflammatory)
8.2.1.1. Neurological Health
Management
8.2.1.2. Inflammatory
8.2.2. Neurological Health Management (Definition,
Market Estimation and Penetration, 2015 – 2018, Market Estimation (2015 –
2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR),
Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and
Africa, Latin America) and Information on Sclerosis, Epilepsy, Alzheimer’s
Disease, Parkinson’s Disease, Huntington’s Disease, Other Diseases)
8.2.2.1. Sclerosis
8.2.2.2. Epilepsy
8.2.2.3. Alzheimer’s Disease
8.2.2.4. Parkinson’s Disease
8.2.2.5. Huntington’s Disease
8.2.2.6. Other Diseases
8.2.3. Mental Health Management (Definition, Market
Estimation and Penetration, 2015 – 2018, Market Estimation (2015 – 2018),
Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Post Traumatic Stress Disorder (PTSD), Depression,
Anxiety, ADHD, Others)
8.2.3.1. Post Traumatic
Stress Disorder (PTSD)
8.2.3.2. Depression
8.2.3.3. Anxiety
8.2.3.4. ADHD
8.2.3.5. Others
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market Estimation
and Penetration, 2015 – 2018
8.2.4.3. Market Forecast,
2019 – 2027
8.2.4.4. Compound Annual
Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015
– 2018
8.2.4.5.1.2. Market Forecast,
2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015
– 2018
8.2.4.5.2.2. Market Forecast,
2019 – 2027
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015
– 2018
8.2.4.5.3.2. Market Forecast,
2019 – 2027
8.2.4.5.4. Middle East and
Africa
8.2.4.5.4.1. Market Estimation, 2015
– 2018
8.2.4.5.4.2. Market Forecast,
2019 – 2027
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015
– 2018
8.2.4.5.5.2. Market Forecast,
2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By Application
9. Global Medical Marijuana Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
9.2.1. Pharmacies
9.2.1.1. Definition
9.2.1.2. Market Estimation
and Penetration, 2015 – 2018
9.2.1.3. Market Forecast,
2019 – 2027
9.2.1.4. Compound Annual
Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015
– 2018
9.2.1.5.1.2. Market Forecast,
2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015
– 2018
9.2.1.5.2.2. Market Forecast,
2019 – 2027
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015
– 2018
9.2.1.5.3.2. Market Forecast,
2019 – 2027
9.2.1.5.4. Middle East and
Africa
9.2.1.5.4.1. Market Estimation, 2015
– 2018
9.2.1.5.4.2. Market Forecast,
2019 – 2027
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015
– 2018
9.2.1.5.5.2. Market Forecast,
2019 – 2027
9.2.2. Hospitals and Dispensaries
9.2.2.1. Definition
9.2.2.2. Market Estimation
and Penetration, 2015 – 2018
9.2.2.3. Market Forecast,
2019 – 2027
9.2.2.4. Compound Annual
Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015
– 2018
9.2.2.5.1.2. Market Forecast,
2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015
– 2018
9.2.2.5.2.2. Market Forecast,
2019 – 2027
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015
– 2018
9.2.2.5.3.2. Market Forecast,
2019 – 2027
9.2.2.5.4. Middle East and
Africa
9.2.2.5.4.1. Market Estimation, 2015
– 2018
9.2.2.5.4.2. Market Forecast,
2019 – 2027
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015
– 2018
9.2.2.5.5.2. Market Forecast,
2019 – 2027
9.2.3. Online Retailers
9.2.3.1. Definition
9.2.3.2. Market Estimation
and Penetration, 2015 – 2018
9.2.3.3. Market Forecast,
2019 – 2027
9.2.3.4. Compound Annual
Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015
– 2018
9.2.3.5.1.2. Market Forecast,
2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015
– 2018
9.2.3.5.2.2. Market Forecast,
2019 – 2027
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015
– 2018
9.2.3.5.3.2. Market Forecast,
2019 – 2027
9.2.3.5.4. Middle East and
Africa
9.2.3.5.4.1. Market Estimation, 2015
– 2018
9.2.3.5.4.2. Market Forecast,
2019 – 2027
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015
– 2018
9.2.3.5.5.2. Market Forecast,
2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By Distribution Channel
10. Global Medical Marijuana Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Type
10.2.1. Indica
10.2.1.1. Definition
10.2.1.2. Market Estimation
and Penetration, 2015 – 2018
10.2.1.3. Market Forecast,
2019 – 2027
10.2.1.4. Compound Annual
Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015
– 2018
10.2.1.5.1.2. Market Forecast,
2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015
– 2018
10.2.1.5.2.2. Market Forecast,
2019 – 2027
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015
– 2018
10.2.1.5.3.2. Market Forecast,
2019 – 2027
10.2.1.5.4. Middle East and
Africa
10.2.1.5.4.1. Market Estimation, 2015
– 2018
10.2.1.5.4.2. Market Forecast,
2019 – 2027
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015
– 2018
10.2.1.5.5.2. Market Forecast,
2019 – 2027
10.2.2. Sativa
10.2.2.1. Definition
10.2.2.2. Market Estimation
and Penetration, 2015 – 2018
10.2.2.3. Market Forecast,
2019 – 2027
10.2.2.4. Compound Annual
Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015
– 2018
10.2.2.5.1.2. Market Forecast,
2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015
– 2018
10.2.2.5.2.2. Market Forecast,
2019 – 2027
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015
– 2018
10.2.2.5.3.2. Market Forecast,
2019 – 2027
10.2.2.5.4. Middle East and
Africa
10.2.2.5.4.1. Market Estimation, 2015
– 2018
10.2.2.5.4.2. Market Forecast,
2019 – 2027
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015
– 2018
10.2.2.5.5.2. Market Forecast,
2019 – 2027
10.2.3. Hybrid
10.2.3.1. Definition
10.2.3.2. Market Estimation
and Penetration, 2015 – 2018
10.2.3.3. Market Forecast,
2019 – 2027
10.2.3.4. Compound Annual
Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015
– 2018
10.2.3.5.1.2. Market Forecast,
2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015
– 2018
10.2.3.5.2.2. Market Forecast,
2019 – 2027
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015
– 2018
10.2.3.5.3.2. Market Forecast,
2019 – 2027
10.2.3.5.4. Middle East and
Africa
10.2.3.5.4.1. Market Estimation, 2015
– 2018
10.2.3.5.4.2. Market Forecast,
2019 – 2027
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015
– 2018
10.2.3.5.5.2. Market Forecast,
2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By Type
11. Global Medical Marijuana Market Analysis and Forecasts, 2019 – 2027
11.1. Overview
11.2. Global Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By Form
11.2.1. Capsule
11.2.1.1. Definition
11.2.1.2. Market Estimation
and Penetration, 2015 – 2018
11.2.1.3. Market Forecast,
2019 – 2027
11.2.1.4. Compound Annual
Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015
– 2018
11.2.1.5.1.2. Market Forecast,
2019 – 2027
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015
– 2018
11.2.1.5.2.2. Market Forecast,
2019 – 2027
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015
– 2018
11.2.1.5.3.2. Market Forecast,
2019 – 2027
11.2.1.5.4. Middle East and
Africa
11.2.1.5.4.1. Market Estimation, 2015
– 2018
11.2.1.5.4.2. Market Forecast,
2019 – 2027
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015
– 2018
11.2.1.5.5.2. Market Forecast,
2019 – 2027
11.2.2. Spray
11.2.2.1. Definition
11.2.2.2. Market Estimation
and Penetration, 2015 – 2018
11.2.2.3. Market Forecast,
2019 – 2027
11.2.2.4. Compound Annual
Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015
– 2018
11.2.2.5.1.2. Market Forecast,
2019 – 2027
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015
– 2018
11.2.2.5.2.2. Market Forecast,
2019 – 2027
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015
– 2018
11.2.2.5.3.2. Market Forecast,
2019 – 2027
11.2.2.5.4. Middle East and
Africa
11.2.2.5.4.1. Market Estimation, 2015
– 2018
11.2.2.5.4.2. Market Forecast,
2019 – 2027
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015
– 2018
11.2.2.5.5.2. Market Forecast,
2019 – 2027
11.2.3. Oil
11.2.3.1. Definition
11.2.3.2. Market Estimation
and Penetration, 2015 – 2018
11.2.3.3. Market Forecast,
2019 – 2027
11.2.3.4. Compound Annual
Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015
– 2018
11.2.3.5.1.2. Market Forecast,
2019 – 2027
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015
– 2018
11.2.3.5.2.2. Market Forecast,
2019 – 2027
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015
– 2018
11.2.3.5.3.2. Market Forecast,
2019 – 2027
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015
– 2018
11.2.3.5.4.2. Market Forecast,
2019 – 2027
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015
– 2018
11.2.3.5.5.2. Market Forecast,
2019 – 2027
11.2.4. Other
11.2.4.1. Definition
11.2.4.2. Market Estimation
and Penetration, 2015 – 2018
11.2.4.3. Market Forecast,
2019 – 2027
11.2.4.4. Compound Annual Growth
Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market Estimation, 2015
– 2018
11.2.4.5.1.2. Market Forecast,
2019 – 2027
11.2.4.5.2. Europe
11.2.4.5.2.1. Market Estimation, 2015
– 2018
11.2.4.5.2.2. Market Forecast,
2019 – 2027
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market Estimation, 2015
– 2018
11.2.4.5.3.2. Market Forecast,
2019 – 2027
11.2.4.5.4. Middle East and
Africa
11.2.4.5.4.1. Market Estimation, 2015
– 2018
11.2.4.5.4.2. Market Forecast,
2019 – 2027
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market Estimation, 2015
– 2018
11.2.4.5.5.2. Market Forecast,
2019 – 2027
11.3. Key
Segment for Channeling Investments
11.3.1. By Form
12. North America Medical Marijuana Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. North America Medical Marijuana Market Revenue (US$ Mn)
12.2. North America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Application
12.2.1. Pain Management
12.2.1.1. Neurological Health
Management
12.2.1.2. Inflammatory
12.2.2. Neurological Health Management
12.2.2.1. Sclerosis
12.2.2.2. Epilepsy
12.2.2.3. Alzheimer’s Disease
12.2.2.4. Parkinson’s Disease
12.2.2.5. Huntington’s Disease
12.2.2.6. Other Diseases
12.2.3. Mental Health Management
12.2.3.1. Post Traumatic
Stress Disorder (PTSD)
12.2.3.2. Depression
12.2.3.3. Anxiety
12.2.3.4. ADHD
12.2.3.5. Others
12.2.4. Others
12.3. North America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.3.1. Pharmacies
12.3.2. Hospitals and Dispensaries
12.3.3. Online Retailers
12.4. North America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Type
12.4.1. Indica
12.4.2. Sativa
12.4.3. Hybrid
12.5. North America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Form
12.5.1. Capsule
12.5.2. Spray
12.5.3. Oil
12.5.4. Other
12.6. North America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.1.1.1. Pain Management
12.6.1.1.1.1. Neurological Health
Management
12.6.1.1.1.2. Inflammatory
12.6.1.1.2. Neurological Health
Management
12.6.1.1.2.1. Sclerosis
12.6.1.1.2.2. Epilepsy
12.6.1.1.2.3. Alzheimer’s Disease
12.6.1.1.2.4. Parkinson’s Disease
12.6.1.1.2.5. Huntington’s Disease
12.6.1.1.2.6. Other Diseases
12.6.1.1.3. Mental Health
Management
12.6.1.1.3.1. Post Traumatic
Stress Disorder (PTSD)
12.6.1.1.3.2. Depression
12.6.1.1.3.3. Anxiety
12.6.1.1.3.4. ADHD
12.6.1.1.3.5. Others
12.6.1.1.4. Others
12.6.1.2. U.S Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.6.1.2.1. Pharmacies
12.6.1.2.2. Hospitals and
Dispensaries
12.6.1.2.3. Online Retailers
12.6.1.3. U.S Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
12.6.1.3.1. Indica
12.6.1.3.2. Sativa
12.6.1.3.3. Hybrid
12.6.1.4. U.S Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
12.6.1.4.1. Capsule
12.6.1.4.2. Spray
12.6.1.4.3. Oil
12.6.1.4.4. Other
12.6.2. Canada
12.6.2.1. Canada Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.2.1.1. Pain Management
12.6.2.1.1.1. Neurological Health
Management
12.6.2.1.1.2. Inflammatory
12.6.2.1.2. Neurological Health
Management
12.6.2.1.2.1. Sclerosis
12.6.2.1.2.2. Epilepsy
12.6.2.1.2.3. Alzheimer’s Disease
12.6.2.1.2.4. Parkinson’s Disease
12.6.2.1.2.5. Huntington’s Disease
12.6.2.1.2.6. Other Diseases
12.6.2.1.3. Mental Health
Management
12.6.2.1.3.1. Post Traumatic
Stress Disorder (PTSD)
12.6.2.1.3.2. Depression
12.6.2.1.3.3. Anxiety
12.6.2.1.3.4. ADHD
12.6.2.1.3.5. Others
12.6.2.1.4. Others
12.6.2.2. Canada Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.6.2.2.1. Pharmacies
12.6.2.2.2. Hospitals and
Dispensaries
12.6.2.2.3. Online Retailers
12.6.2.3. Canada Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
12.6.2.3.1. Indica
12.6.2.3.2. Sativa
12.6.2.3.3. Hybrid
12.6.2.4. Canada Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
12.6.2.4.1. Capsule
12.6.2.4.2. Spray
12.6.2.4.3. Oil
12.6.2.4.4. Other
12.6.3. Mexico
12.6.3.1. Mexico Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.3.1.1. Pain Management
12.6.3.1.1.1. Neurological Health
Management
12.6.3.1.1.2. Inflammatory
12.6.3.1.2. Neurological Health
Management
12.6.3.1.2.1. Sclerosis
12.6.3.1.2.2. Epilepsy
12.6.3.1.2.3. Alzheimer’s Disease
12.6.3.1.2.4. Parkinson’s Disease
12.6.3.1.2.5. Huntington’s Disease
12.6.3.1.2.6. Other Diseases
12.6.3.1.3. Mental Health
Management
12.6.3.1.3.1. Post Traumatic
Stress Disorder (PTSD)
12.6.3.1.3.2. Depression
12.6.3.1.3.3. Anxiety
12.6.3.1.3.4. ADHD
12.6.3.1.3.5. Others
12.6.3.1.4. Others
12.6.3.2. Mexico Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.6.3.2.1. Pharmacies
12.6.3.2.2. Hospitals and
Dispensaries
12.6.3.2.3. Online Retailers
12.6.3.3. Mexico Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
12.6.3.3.1. Indica
12.6.3.3.2. Sativa
12.6.3.3.3. Hybrid
12.6.3.4. Mexico Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
12.6.3.4.1. Capsule
12.6.3.4.2. Spray
12.6.3.4.3. Oil
12.6.3.4.4. Other
12.6.4. Rest of North America
12.6.4.1. Rest of North
America Medical Marijuana Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.4.1.1. Pain Management
12.6.4.1.1.1. Neurological Health
Management
12.6.4.1.1.2. Inflammatory
12.6.4.1.2. Neurological Health
Management
12.6.4.1.2.1. Sclerosis
12.6.4.1.2.2. Epilepsy
12.6.4.1.2.3. Alzheimer’s Disease
12.6.4.1.2.4. Parkinson’s Disease
12.6.4.1.2.5. Huntington’s Disease
12.6.4.1.2.6. Other Diseases
12.6.4.1.3. Mental Health
Management
12.6.4.1.3.1. Post Traumatic
Stress Disorder (PTSD)
12.6.4.1.3.2. Depression
12.6.4.1.3.3. Anxiety
12.6.4.1.3.4. ADHD
12.6.4.1.3.5. Others
12.6.4.1.4. Others
12.6.4.2. Rest of North
America Medical Marijuana Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
12.6.4.2.1. Pharmacies
12.6.4.2.2. Hospitals and
Dispensaries
12.6.4.2.3. Online Retailers
12.6.4.3. Rest of North
America Medical Marijuana Market Revenue
(US$ Mn) and Forecasts, By Type
12.6.4.3.1. Indica
12.6.4.3.2. Sativa
12.6.4.3.3. Hybrid
12.6.4.4. Rest of North
America Medical Marijuana Market Revenue
(US$ Mn) and Forecasts, By Form
12.6.4.4.1. Capsule
12.6.4.4.2. Spray
12.6.4.4.3. Oil
12.6.4.4.4. Other
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Application
12.7.3. By Distribution Channel
12.7.4. By Type
12.7.5. By Form
13. Europe Medical Marijuana Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Europe Medical Marijuana Market Revenue (US$ Mn)
13.2. Europe Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Application
13.2.1. Pain Management
13.2.1.1. Neurological Health
Management
13.2.1.2. Inflammatory
13.2.2. Neurological Health Management
13.2.2.1. Sclerosis
13.2.2.2. Epilepsy
13.2.2.3. Alzheimer’s Disease
13.2.2.4. Parkinson’s Disease
13.2.2.5. Huntington’s Disease
13.2.2.6. Other Diseases
13.2.3. Mental Health Management
13.2.3.1. Post Traumatic
Stress Disorder (PTSD)
13.2.3.2. Depression
13.2.3.3. Anxiety
13.2.3.4. ADHD
13.2.3.5. Others
13.2.4. Others
13.3. Europe Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.3.1. Pharmacies
13.3.2. Hospitals and Dispensaries
13.3.3. Online Retailers
13.4. Europe Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Type
13.4.1. Indica
13.4.2. Sativa
13.4.3. Hybrid
13.5. Europe Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Form
13.5.1. Capsule
13.5.2. Spray
13.5.3. Oil
13.5.4. Other
13.6. Europe Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.1. The UK
13.6.1.1. The UK Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.1.1.1. Pain Management
13.6.1.1.1.1. Neurological Health
Management
13.6.1.1.1.2. Inflammatory
13.6.1.1.2. Neurological Health
Management
13.6.1.1.2.1. Sclerosis
13.6.1.1.2.2. Epilepsy
13.6.1.1.2.3. Alzheimer’s Disease
13.6.1.1.2.4. Parkinson’s Disease
13.6.1.1.2.5. Huntington’s Disease
13.6.1.1.2.6. Other Diseases
13.6.1.1.3. Mental Health
Management
13.6.1.1.3.1. Post Traumatic
Stress Disorder (PTSD)
13.6.1.1.3.2. Depression
13.6.1.1.3.3. Anxiety
13.6.1.1.3.4. ADHD
13.6.1.1.3.5. Others
13.6.1.1.4. Others
13.6.1.2. The UK Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.1.2.1. Pharmacies
13.6.1.2.2. Hospitals and
Dispensaries
13.6.1.2.3. Online Retailers
13.6.1.3. The UK Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.1.3.1. Indica
13.6.1.3.2. Sativa
13.6.1.3.3. Hybrid
13.6.1.4. The UK Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
13.6.1.4.1. Capsule
13.6.1.4.2. Spray
13.6.1.4.3. Oil
13.6.1.4.4. Other
13.6.2. Germany
13.6.2.1. Germany Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.2.1.1. Pain Management
13.6.2.1.1.1. Neurological Health
Management
13.6.2.1.1.2. Inflammatory
13.6.2.1.2. Neurological Health
Management
13.6.2.1.2.1. Sclerosis
13.6.2.1.2.2. Epilepsy
13.6.2.1.2.3. Alzheimer’s Disease
13.6.2.1.2.4. Parkinson’s Disease
13.6.2.1.2.5. Huntington’s Disease
13.6.2.1.2.6. Other Diseases
13.6.2.1.3. Mental Health
Management
13.6.2.1.3.1. Post Traumatic
Stress Disorder (PTSD)
13.6.2.1.3.2. Depression
13.6.2.1.3.3. Anxiety
13.6.2.1.3.4. ADHD
13.6.2.1.3.5. Others
13.6.2.1.4. Others
13.6.2.2. Germany Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.2.2.1. Pharmacies
13.6.2.2.2. Hospitals and
Dispensaries
13.6.2.2.3. Online Retailers
13.6.2.3. Germany Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.2.3.1. Indica
13.6.2.3.2. Sativa
13.6.2.3.3. Hybrid
13.6.2.4. Germany Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
13.6.2.4.1. Capsule
13.6.2.4.2. Spray
13.6.2.4.3. Oil
13.6.2.4.4. Other
13.6.3. Italy
13.6.3.1. Italy Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.3.1.1. Pain Management
13.6.3.1.1.1. Neurological Health
Management
13.6.3.1.1.2. Inflammatory
13.6.3.1.2. Neurological Health
Management
13.6.3.1.2.1. Sclerosis
13.6.3.1.2.2. Epilepsy
13.6.3.1.2.3. Alzheimer’s Disease
13.6.3.1.2.4. Parkinson’s Disease
13.6.3.1.2.5. Huntington’s Disease
13.6.3.1.2.6. Other Diseases
13.6.3.1.3. Mental Health
Management
13.6.3.1.3.1. Post Traumatic
Stress Disorder (PTSD)
13.6.3.1.3.2. Depression
13.6.3.1.3.3. Anxiety
13.6.3.1.3.4. ADHD
13.6.3.1.3.5. Others
13.6.3.1.4. Others
13.6.3.2. Italy Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.3.2.1. Pharmacies
13.6.3.2.2. Hospitals and
Dispensaries
13.6.3.2.3. Online Retailers
13.6.3.3. Italy Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.3.3.1. Indica
13.6.3.3.2. Sativa
13.6.3.3.3. Hybrid
13.6.3.4. Italy Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
13.6.3.4.1. Capsule
13.6.3.4.2. Spray
13.6.3.4.3. Oil
13.6.3.4.4. Other
13.6.4. Switzerland
13.6.4.1. Switzerland Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.4.1.1. Pain Management
13.6.4.1.1.1. Neurological Health
Management
13.6.4.1.1.2. Inflammatory
13.6.4.1.2. Neurological Health
Management
13.6.4.1.2.1. Sclerosis
13.6.4.1.2.2. Epilepsy
13.6.4.1.2.3. Alzheimer’s Disease
13.6.4.1.2.4. Parkinson’s Disease
13.6.4.1.2.5. Huntington’s Disease
13.6.4.1.2.6. Other Diseases
13.6.4.1.3. Mental Health
Management
13.6.4.1.3.1. Post Traumatic
Stress Disorder (PTSD)
13.6.4.1.3.2. Depression
13.6.4.1.3.3. Anxiety
13.6.4.1.3.4. ADHD
13.6.4.1.3.5. Others
13.6.4.1.4. Others
13.6.4.2. Switzerland Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.4.2.1. Pharmacies
13.6.4.2.2. Hospitals and
Dispensaries
13.6.4.2.3. Online Retailers
13.6.4.3. Switzerland Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.4.3.1. Indica
13.6.4.3.2. Sativa
13.6.4.3.3. Hybrid
13.6.4.4. Switzerland Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
13.6.4.4.1. Capsule
13.6.4.4.2. Spray
13.6.4.4.3. Oil
13.6.4.4.4. Other
13.6.5. Nordic Countries
13.6.5.1. Nordic Countries
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Application
13.6.5.1.1. Pain Management
13.6.5.1.1.1. Neurological Health
Management
13.6.5.1.1.2. Inflammatory
13.6.5.1.2. Neurological Health
Management
13.6.5.1.2.1. Sclerosis
13.6.5.1.2.2. Epilepsy
13.6.5.1.2.3. Alzheimer’s Disease
13.6.5.1.2.4. Parkinson’s Disease
13.6.5.1.2.5. Huntington’s Disease
13.6.5.1.2.6. Other Diseases
13.6.5.1.3. Mental Health
Management
13.6.5.1.3.1. Post Traumatic
Stress Disorder (PTSD)
13.6.5.1.3.2. Depression
13.6.5.1.3.3. Anxiety
13.6.5.1.3.4. ADHD
13.6.5.1.3.5. Others
13.6.5.1.4. Others
13.6.5.2. Nordic Countries
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.5.2.1. Pharmacies
13.6.5.2.2. Hospitals and
Dispensaries
13.6.5.2.3. Online Retailers
13.6.5.3. Nordic Countries
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Type
13.6.5.3.1. Indica
13.6.5.3.2. Sativa
13.6.5.3.3. Hybrid
13.6.5.4. Nordic Countries
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Form
13.6.5.4.1. Capsule
13.6.5.4.2. Spray
13.6.5.4.3. Oil
13.6.5.4.4. Other
13.6.5.5. Nordic Countries
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Country
13.6.5.5.1. Denmark
13.6.5.5.2. Finland
13.6.5.5.3. Norway
13.6.6. Benelux Union
13.6.6.1. Benelux Union
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Application
13.6.6.1.1. Pain Management
13.6.6.1.1.1. Neurological Health
Management
13.6.6.1.1.2. Inflammatory
13.6.6.1.2. Neurological Health
Management
13.6.6.1.2.1. Sclerosis
13.6.6.1.2.2. Epilepsy
13.6.6.1.2.3. Alzheimer’s Disease
13.6.6.1.2.4. Parkinson’s Disease
13.6.6.1.2.5. Huntington’s Disease
13.6.6.1.2.6. Other Diseases
13.6.6.1.3. Mental Health Management
13.6.6.1.3.1. Post Traumatic
Stress Disorder (PTSD)
13.6.6.1.3.2. Depression
13.6.6.1.3.3. Anxiety
13.6.6.1.3.4. ADHD
13.6.6.1.3.5. Others
13.6.6.1.4. Others
13.6.6.2. Benelux Union
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.6.2.1. Pharmacies
13.6.6.2.2. Hospitals and
Dispensaries
13.6.6.2.3. Online Retailers
13.6.6.3. Benelux Union Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.6.3.1. Indica
13.6.6.3.2. Sativa
13.6.6.3.3. Hybrid
13.6.6.4. Benelux Union
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Form
13.6.6.4.1. Capsule
13.6.6.4.2. Spray
13.6.6.4.3. Oil
13.6.6.4.4. Other
13.6.6.5. Benelux Union
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Country
13.6.6.5.1. Belgium
13.6.6.5.2. The Netherlands
13.6.6.5.3. Luxembourg
13.6.7. Rest of Europe
13.6.7.1. Rest of Europe
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Application
13.6.7.1.1. Pain Management
13.6.7.1.1.1. Neurological Health
Management
13.6.7.1.1.2. Inflammatory
13.6.7.1.2. Neurological Health
Management
13.6.7.1.2.1. Sclerosis
13.6.7.1.2.2. Epilepsy
13.6.7.1.2.3. Alzheimer’s Disease
13.6.7.1.2.4. Parkinson’s Disease
13.6.7.1.2.5. Huntington’s Disease
13.6.7.1.2.6. Other Diseases
13.6.7.1.3. Mental Health
Management
13.6.7.1.3.1. Post Traumatic
Stress Disorder (PTSD)
13.6.7.1.3.2. Depression
13.6.7.1.3.3. Anxiety
13.6.7.1.3.4. ADHD
13.6.7.1.3.5. Others
13.6.7.1.4. Others
13.6.7.2. Rest of Europe
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.7.2.1. Pharmacies
13.6.7.2.2. Hospitals and
Dispensaries
13.6.7.2.3. Online Retailers
13.6.7.3. Rest of Europe
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Type
13.6.7.3.1. Indica
13.6.7.3.2. Sativa
13.6.7.3.3. Hybrid
13.6.7.4. Rest of Europe
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Form
13.6.7.4.1. Capsule
13.6.7.4.2. Spray
13.6.7.4.3. Oil
13.6.7.4.4. Other
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Application
13.7.3. By Distribution Channel
13.7.4. By Type
13.7.5. By Form
14. Asia Pacific Medical Marijuana Market Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Asia Pacific Medical Marijuana Market Revenue (US$ Mn)
14.2. Asia Pacific Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Application
14.2.1. Pain Management
14.2.1.1. Neurological Health
Management
14.2.1.2. Inflammatory
14.2.2. Neurological Health Management
14.2.2.1. Sclerosis
14.2.2.2. Epilepsy
14.2.2.3. Alzheimer’s Disease
14.2.2.4. Parkinson’s Disease
14.2.2.5. Huntington’s Disease
14.2.2.6. Other Diseases
14.2.3. Mental Health Management
14.2.3.1. Post Traumatic
Stress Disorder (PTSD)
14.2.3.2. Depression
14.2.3.3. Anxiety
14.2.3.4. ADHD
14.2.3.5. Others
14.2.4. Others
14.3. Asia Pacific Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.3.1. Pharmacies
14.3.2. Hospitals and Dispensaries
14.3.3. Online Retailers
14.4. Asia Pacific Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Type
14.4.1. Indica
14.4.2. Sativa
14.4.3. Hybrid
14.5. Asia Pacific Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Form
14.5.1. Capsule
14.5.2. Spray
14.5.3. Oil
14.5.4. Other
14.6. Asia Pacific Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. New Zealand
14.6.1.1. New Zealand Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.1.1.1. Pain Management
14.6.1.1.1.1. Neurological Health
Management
14.6.1.1.1.2. Inflammatory
14.6.1.1.2. Neurological Health
Management
14.6.1.1.2.1. Sclerosis
14.6.1.1.2.2. Epilepsy
14.6.1.1.2.3. Alzheimer’s Disease
14.6.1.1.2.4. Parkinson’s Disease
14.6.1.1.2.5. Huntington’s Disease
14.6.1.1.2.6. Other Diseases
14.6.1.1.3. Mental Health
Management
14.6.1.1.3.1. Post Traumatic
Stress Disorder (PTSD)
14.6.1.1.3.2. Depression
14.6.1.1.3.3. Anxiety
14.6.1.1.3.4. ADHD
14.6.1.1.3.5. Others
14.6.1.1.4. Others
14.6.1.2. New Zealand Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.1.2.1. Pharmacies
14.6.1.2.2. Hospitals and
Dispensaries
14.6.1.2.3. Online Retailers
14.6.1.3. New Zealand Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.1.3.1. Indica
14.6.1.3.2. Sativa
14.6.1.3.3. Hybrid
14.6.1.4. New Zealand Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
14.6.1.4.1. Capsule
14.6.1.4.2. Spray
14.6.1.4.3. Oil
14.6.1.4.4. Other
14.6.2. Australia
14.6.2.1. Australia Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.2.1.1. Pain Management
14.6.2.1.1.1. Neurological Health
Management
14.6.2.1.1.2. Inflammatory
14.6.2.1.2. Neurological Health
Management
14.6.2.1.2.1. Sclerosis
14.6.2.1.2.2. Epilepsy
14.6.2.1.2.3. Alzheimer’s Disease
14.6.2.1.2.4. Parkinson’s Disease
14.6.2.1.2.5. Huntington’s Disease
14.6.2.1.2.6. Other Diseases
14.6.2.1.3. Mental Health
Management
14.6.2.1.3.1. Post Traumatic
Stress Disorder (PTSD)
14.6.2.1.3.2. Depression
14.6.2.1.3.3. Anxiety
14.6.2.1.3.4. ADHD
14.6.2.1.3.5. Others
14.6.2.1.4. Others
14.6.2.2. Australia Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.2.2.1. Pharmacies
14.6.2.2.2. Hospitals and
Dispensaries
14.6.2.2.3. Online Retailers
14.6.2.3. Australia Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.2.3.1. Indica
14.6.2.3.2. Sativa
14.6.2.3.3. Hybrid
14.6.2.4. Australia Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
14.6.2.4.1. Capsule
14.6.2.4.2. Spray
14.6.2.4.3. Oil
14.6.2.4.4. Other
14.6.3. South Korea
14.6.3.1. South Korea Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.3.1.1. Pain Management
14.6.3.1.1.1. Neurological Health
Management
14.6.3.1.1.2. Inflammatory
14.6.3.1.2. Neurological Health
Management
14.6.3.1.2.1. Sclerosis
14.6.3.1.2.2. Epilepsy
14.6.3.1.2.3. Alzheimer’s Disease
14.6.3.1.2.4. Parkinson’s Disease
14.6.3.1.2.5. Huntington’s Disease
14.6.3.1.2.6. Other Diseases
14.6.3.1.3. Mental Health
Management
14.6.3.1.3.1. Post Traumatic
Stress Disorder (PTSD)
14.6.3.1.3.2. Depression
14.6.3.1.3.3. Anxiety
14.6.3.1.3.4. ADHD
14.6.3.1.3.5. Others
14.6.3.1.4. Others
14.6.3.2. South Korea Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.3.2.1. Pharmacies
14.6.3.2.2. Hospitals and
Dispensaries
14.6.3.2.3. Online Retailers
14.6.3.3. South Korea Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.3.3.1. Indica
14.6.3.3.2. Sativa
14.6.3.3.3. Hybrid
14.6.3.4. South Korea Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
14.6.3.4.1. Capsule
14.6.3.4.2. Spray
14.6.3.4.3. Oil
14.6.3.4.4. Other
14.6.4. Southeast Asia
14.6.4.1. Southeast Asia
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Application
14.6.4.1.1. Pain Management
14.6.4.1.1.1. Neurological Health
Management
14.6.4.1.1.2. Inflammatory
14.6.4.1.2. Neurological Health
Management
14.6.4.1.2.1. Sclerosis
14.6.4.1.2.2. Epilepsy
14.6.4.1.2.3. Alzheimer’s Disease
14.6.4.1.2.4. Parkinson’s Disease
14.6.4.1.2.5. Huntington’s Disease
14.6.4.1.2.6. Other Diseases
14.6.4.1.3. Mental Health
Management
14.6.4.1.3.1. Post Traumatic
Stress Disorder (PTSD)
14.6.4.1.3.2. Depression
14.6.4.1.3.3. Anxiety
14.6.4.1.3.4. ADHD
14.6.4.1.3.5. Others
14.6.4.1.4. Others
14.6.4.2. Southeast Asia
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.4.2.1. Pharmacies
14.6.4.2.2. Hospitals and
Dispensaries
14.6.4.2.3. Online Retailers
14.6.4.3. Southeast Asia
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Type
14.6.4.3.1. Indica
14.6.4.3.2. Sativa
14.6.4.3.3. Hybrid
14.6.4.4. Southeast Asia
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Form
14.6.4.4.1. Capsule
14.6.4.4.2. Spray
14.6.4.4.3. Oil
14.6.4.4.4. Other
14.6.4.5. Southeast Asia
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Country
14.6.4.5.1. Thailand
14.6.4.5.2. Malaysia
14.6.4.5.3. Rest of Southeast
Asia
14.6.5. Rest of Asia Pacific
14.6.5.1. Rest of Asia Pacific
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Application
14.6.5.1.1. Pain Management
14.6.5.1.1.1. Neurological Health
Management
14.6.5.1.1.2. Inflammatory
14.6.5.1.2. Neurological Health
Management
14.6.5.1.2.1. Sclerosis
14.6.5.1.2.2. Epilepsy
14.6.5.1.2.3. Alzheimer’s Disease
14.6.5.1.2.4. Parkinson’s Disease
14.6.5.1.2.5. Huntington’s Disease
14.6.5.1.2.6. Other Diseases
14.6.5.1.3. Mental Health
Management
14.6.5.1.3.1. Post Traumatic
Stress Disorder (PTSD)
14.6.5.1.3.2. Depression
14.6.5.1.3.3. Anxiety
14.6.5.1.3.4. ADHD
14.6.5.1.3.5. Others
14.6.5.1.4. Others
14.6.5.2. Rest of Asia Pacific
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.5.2.1. Pharmacies
14.6.5.2.2. Hospitals and
Dispensaries
14.6.5.2.3. Online Retailers
14.6.5.3. Rest of Asia Pacific
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Type
14.6.5.3.1. Indica
14.6.5.3.2. Sativa
14.6.5.3.3. Hybrid
14.6.5.4. Rest of Asia Pacific
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Form
14.6.5.4.1. Capsule
14.6.5.4.2. Spray
14.6.5.4.3. Oil
14.6.5.4.4. Other
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Application
14.7.3. By Distribution Channel
14.7.4. By Type
14.7.5. By Form
15. Middle East and Africa Medical Marijuana Market Analysis and Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Middle East and Africa Medical Marijuana Market Revenue (US$ Mn)
15.2. Middle East and Africa Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Application
15.2.1. Pain Management
15.2.1.1. Neurological Health
Management
15.2.1.2. Inflammatory
15.2.2. Neurological Health Management
15.2.2.1. Sclerosis
15.2.2.2. Epilepsy
15.2.2.3. Alzheimer’s Disease
15.2.2.4. Parkinson’s Disease
15.2.2.5. Huntington’s Disease
15.2.2.6. Other Diseases
15.2.3. Mental Health Management
15.2.3.1. Post Traumatic
Stress Disorder (PTSD)
15.2.3.2. Depression
15.2.3.3. Anxiety
15.2.3.4. ADHD
15.2.3.5. Others
15.2.4. Others
15.3. Middle East and Africa Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.3.1. Pharmacies
15.3.2. Hospitals and Dispensaries
15.3.3. Online Retailers
15.4. Middle East and Africa Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Type
15.4.1. Indica
15.4.2. Sativa
15.4.3. Hybrid
15.5. Middle East and Africa Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Form
15.5.1. Capsule
15.5.2. Spray
15.5.3. Oil
15.5.4. Other
15.6. Middle East and Africa Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Country
15.6.1. Israel
15.6.1.1. Israel Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.1.1.1. Pain Management
15.6.1.1.1.1. Neurological Health
Management
15.6.1.1.1.2. Inflammatory
15.6.1.1.2. Neurological Health
Management
15.6.1.1.2.1. Sclerosis
15.6.1.1.2.2. Epilepsy
15.6.1.1.2.3. Alzheimer’s Disease
15.6.1.1.2.4. Parkinson’s Disease
15.6.1.1.2.5. Huntington’s Disease
15.6.1.1.2.6. Other Diseases
15.6.1.1.3. Mental Health
Management
15.6.1.1.3.1. Post Traumatic
Stress Disorder (PTSD)
15.6.1.1.3.2. Depression
15.6.1.1.3.3. Anxiety
15.6.1.1.3.4. ADHD
15.6.1.1.3.5. Others
15.6.1.1.4. Others
15.6.1.2. Israel Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.1.2.1. Pharmacies
15.6.1.2.2. Hospitals and
Dispensaries
15.6.1.2.3. Online Retailers
15.6.1.3. Israel Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.1.3.1. Indica
15.6.1.3.2. Sativa
15.6.1.3.3. Hybrid
15.6.1.4. Israel Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
15.6.1.4.1. Capsule
15.6.1.4.2. Spray
15.6.1.4.3. Oil
15.6.1.4.4. Other
15.6.2. Zimbabwe
15.6.2.1. Zimbabwe Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.2.1.1. Pain Management
15.6.2.1.1.1. Neurological Health
Management
15.6.2.1.1.2. Inflammatory
15.6.2.1.2. Neurological Health
Management
15.6.2.1.2.1. Sclerosis
15.6.2.1.2.2. Epilepsy
15.6.2.1.2.3. Alzheimer’s Disease
15.6.2.1.2.4. Parkinson’s Disease
15.6.2.1.2.5. Huntington’s Disease
15.6.2.1.2.6. Other Diseases
15.6.2.1.3. Mental Health
Management
15.6.2.1.3.1. Post Traumatic
Stress Disorder (PTSD)
15.6.2.1.3.2. Depression
15.6.2.1.3.3. Anxiety
15.6.2.1.3.4. ADHD
15.6.2.1.3.5. Others
15.6.2.1.4. Others
15.6.2.2. Zimbabwe Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.2.2.1. Pharmacies
15.6.2.2.2. Hospitals and
Dispensaries
15.6.2.2.3. Online Retailers
15.6.2.3. Zimbabwe Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.2.3.1. Indica
15.6.2.3.2. Sativa
15.6.2.3.3. Hybrid
15.6.2.4. Zimbabwe Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
15.6.2.4.1. Capsule
15.6.2.4.2. Spray
15.6.2.4.3. Oil
15.6.2.4.4. Other
15.6.3. Rest of Middle East & Africa
15.6.3.1. Rest of Middle East
& Africa Medical Marijuana Market
Revenue (US$ Mn) and Forecasts, By Application
15.6.3.1.1. Pain Management
15.6.3.1.1.1. Neurological Health
Management
15.6.3.1.1.2. Inflammatory
15.6.3.1.2. Neurological Health
Management
15.6.3.1.2.1. Sclerosis
15.6.3.1.2.2. Epilepsy
15.6.3.1.2.3. Alzheimer’s Disease
15.6.3.1.2.4. Parkinson’s Disease
15.6.3.1.2.5. Huntington’s Disease
15.6.3.1.2.6. Other Diseases
15.6.3.1.3. Mental Health
Management
15.6.3.1.3.1. Post Traumatic
Stress Disorder (PTSD)
15.6.3.1.3.2. Depression
15.6.3.1.3.3. Anxiety
15.6.3.1.3.4. ADHD
15.6.3.1.3.5. Others
15.6.3.1.4. Others
15.6.3.2. Rest of Middle East
& Africa Medical Marijuana Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.3.2.1. Pharmacies
15.6.3.2.2. Hospitals and
Dispensaries
15.6.3.2.3. Online Retailers
15.6.3.3. Rest of Middle East
& Africa Medical Marijuana Market
Revenue (US$ Mn) and Forecasts, By Type
15.6.3.3.1. Indica
15.6.3.3.2. Sativa
15.6.3.3.3. Hybrid
15.6.3.4. Rest of Middle East
& Africa Medical Marijuana Market
Revenue (US$ Mn) and Forecasts, By Form
15.6.3.4.1. Capsule
15.6.3.4.2. Spray
15.6.3.4.3. Oil
15.6.3.4.4. Other
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Application
15.7.3. By Distribution Channel
15.7.4. By Type
15.7.5. By Form
16. Latin America Medical Marijuana Market Analysis and Forecasts, 2019 - 2027
16.1. Overview
16.1.1. Latin America Medical Marijuana Market Revenue (US$ Mn)
16.2. Latin America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Application
16.2.1. Pain Management
16.2.1.1. Neurological Health
Management
16.2.1.2. Inflammatory
16.2.2. Neurological Health Management
16.2.2.1. Sclerosis
16.2.2.2. Epilepsy
16.2.2.3. Alzheimer’s Disease
16.2.2.4. Parkinson’s Disease
16.2.2.5. Huntington’s Disease
16.2.2.6. Other Diseases
16.2.3. Mental Health Management
16.2.3.1. Post Traumatic
Stress Disorder (PTSD)
16.2.3.2. Depression
16.2.3.3. Anxiety
16.2.3.4. ADHD
16.2.3.5. Others
16.2.4. Others
16.3. Latin America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.3.1. Pharmacies
16.3.2. Hospitals and Dispensaries
16.3.3. Online Retailers
16.4. Latin America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Type
16.4.1. Indica
16.4.2. Sativa
16.4.3. Hybrid
16.5. Latin America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Form
16.5.1. Capsule
16.5.2. Spray
16.5.3. Oil
16.5.4. Other
16.6. Latin America Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.1.1.1. Pain Management
16.6.1.1.1.1. Neurological Health
Management
16.6.1.1.1.2. Inflammatory
16.6.1.1.2. Neurological Health
Management
16.6.1.1.2.1. Sclerosis
16.6.1.1.2.2. Epilepsy
16.6.1.1.2.3. Alzheimer’s Disease
16.6.1.1.2.4. Parkinson’s Disease
16.6.1.1.2.5. Huntington’s Disease
16.6.1.1.2.6. Other Diseases
16.6.1.1.3. Mental Health
Management
16.6.1.1.3.1. Post Traumatic
Stress Disorder (PTSD)
16.6.1.1.3.2. Depression
16.6.1.1.3.3. Anxiety
16.6.1.1.3.4. ADHD
16.6.1.1.3.5. Others
16.6.1.1.4. Others
16.6.1.2. Brazil Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.6.1.2.1. Pharmacies
16.6.1.2.2. Hospitals and
Dispensaries
16.6.1.2.3. Online Retailers
16.6.1.3. Brazil Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
16.6.1.3.1. Indica
16.6.1.3.2. Sativa
16.6.1.3.3. Hybrid
16.6.1.4. Brazil Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
16.6.1.4.1. Capsule
16.6.1.4.2. Spray
16.6.1.4.3. Oil
16.6.1.4.4. Other
16.6.2. Argentina
16.6.2.1. Argentina Medical Marijuana Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.2.1.1. Pain Management
16.6.2.1.1.1. Neurological Health
Management
16.6.2.1.1.2. Inflammatory
16.6.2.1.2. Neurological Health
Management
16.6.2.1.2.1. Sclerosis
16.6.2.1.2.2. Epilepsy
16.6.2.1.2.3. Alzheimer’s Disease
16.6.2.1.2.4. Parkinson’s Disease
16.6.2.1.2.5. Huntington’s Disease
16.6.2.1.2.6. Other Diseases
16.6.2.1.3. Mental Health
Management
16.6.2.1.3.1. Post Traumatic
Stress Disorder (PTSD)
16.6.2.1.3.2. Depression
16.6.2.1.3.3. Anxiety
16.6.2.1.3.4. ADHD
16.6.2.1.3.5. Others
16.6.2.1.4. Others
16.6.2.2. Argentina Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.6.2.2.1. Pharmacies
16.6.2.2.2. Hospitals and
Dispensaries
16.6.2.2.3. Online Retailers
16.6.2.3. Argentina Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
16.6.2.3.1. Indica
16.6.2.3.2. Sativa
16.6.2.3.3. Hybrid
16.6.2.4. Argentina Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
16.6.2.4.1. Capsule
16.6.2.4.2. Spray
16.6.2.4.3. Oil
16.6.2.4.4. Other
16.6.3. Uruguay
16.6.3.1. Uruguay Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.3.1.1. Pain Management
16.6.3.1.1.1. Neurological Health
Management
16.6.3.1.1.2. Inflammatory
16.6.3.1.2. Neurological Health
Management
16.6.3.1.2.1. Sclerosis
16.6.3.1.2.2. Epilepsy
16.6.3.1.2.3. Alzheimer’s Disease
16.6.3.1.2.4. Parkinson’s Disease
16.6.3.1.2.5. Huntington’s Disease
16.6.3.1.2.6. Other Diseases
16.6.3.1.3. Mental Health
Management
16.6.3.1.3.1. Post Traumatic
Stress Disorder (PTSD)
16.6.3.1.3.2. Depression
16.6.3.1.3.3. Anxiety
16.6.3.1.3.4. ADHD
16.6.3.1.3.5. Others
16.6.3.1.4. Others
16.6.3.2. Uruguay Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.6.3.2.1. Pharmacies
16.6.3.2.2. Hospitals and
Dispensaries
16.6.3.2.3. Online Retailers
16.6.3.3. Uruguay Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Type
16.6.3.3.1. Indica
16.6.3.3.2. Sativa
16.6.3.3.3. Hybrid
16.6.3.4. Uruguay Medical
Marijuana Market Revenue (US$ Mn) and
Forecasts, By Form
16.6.3.4.1. Capsule
16.6.3.4.2. Spray
16.6.3.4.3. Oil
16.6.3.4.4. Other
16.6.4. Rest of Latin America
16.6.4.1. Rest of Latin
America Medical Marijuana Market Revenue
(US$ Mn) and Forecasts, By Application
16.6.4.1.1. Pain Management
16.6.4.1.1.1. Neurological Health
Management
16.6.4.1.1.2. Inflammatory
16.6.4.1.2. Neurological Health
Management
16.6.4.1.2.1. Sclerosis
16.6.4.1.2.2. Epilepsy
16.6.4.1.2.3. Alzheimer’s Disease
16.6.4.1.2.4. Parkinson’s Disease
16.6.4.1.2.5. Huntington’s Disease
16.6.4.1.2.6. Other Diseases
16.6.4.1.3. Mental Health
Management
16.6.4.1.3.1. Post Traumatic
Stress Disorder (PTSD)
16.6.4.1.3.2. Depression
16.6.4.1.3.3. Anxiety
16.6.4.1.3.4. ADHD
16.6.4.1.3.5. Others
16.6.4.1.4. Others
16.6.4.2. Rest of Latin
America Medical Marijuana Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
16.6.4.2.1. Pharmacies
16.6.4.2.2. Hospitals and
Dispensaries
16.6.4.2.3. Online Retailers
16.6.4.3. Rest of Latin America
Medical Marijuana Market Revenue (US$
Mn) and Forecasts, By Type
16.6.4.3.1. Indica
16.6.4.3.2. Sativa
16.6.4.3.3. Hybrid
16.6.4.4. Rest of Latin
America Medical Marijuana Market Revenue
(US$ Mn) and Forecasts, By Form
16.6.4.4.1. Capsule
16.6.4.4.2. Spray
16.6.4.4.3. Oil
16.6.4.4.4. Other
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Application
16.7.3. By Distribution Channel
16.7.4. By Type
16.7.5. By Form
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2018
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Abattis Bioceuticals Corp.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Agripharm Corp.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Aurora Cannabis Enterprises Inc.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Cannabis Sativa, Inc.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. CannaGrow Holdings, Inc.
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Canopy Growth Corporation
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Cara Therapeutics, Inc
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Cresco Labs, LLC
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Emerald Health Botanicals Inc.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Growblox Sciences, Inc.
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. GW Pharmaceuticals plc
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Insys Therapeutics, Inc.
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Lexaria Corp.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Medical Marijuana Inc.
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. Novartis International AG
18.15.1. Company Details
18.15.2. Company Overview
18.15.3. Product Offerings
18.15.4. Key Developments
18.15.5. Financial Analysis
18.15.6. SWOT Analysis
18.15.7. Business Strategies
18.16. Pfizer, Inc.
18.16.1. Company Details
18.16.2. Company Overview
18.16.3. Product Offerings
18.16.4. Key Developments
18.16.5. Financial Analysis
18.16.6. SWOT Analysis
18.16.7. Business Strategies
18.17. Teva Pharmaceuticals USA, Inc.
18.17.1. Company Details
18.17.2. Company Overview
18.17.3. Product Offerings
18.17.4. Key Developments
18.17.5. Financial Analysis
18.17.6. SWOT Analysis
18.17.7. Business Strategies
18.18. Tweed Inc.
18.18.1. Company Details
18.18.2. Company Overview
18.18.3. Product Offerings
18.18.4. Key Developments
18.18.5. Financial Analysis
18.18.6. SWOT Analysis
18.18.7. Business Strategies
18.19. United Cannabis Corporation
18.19.1. Company Details
18.19.2. Company Overview
18.19.3. Product Offerings
18.19.4. Key Developments
18.19.5. Financial Analysis
18.19.6. SWOT Analysis
18.19.7. Business Strategies
18.20. Whistler Medical Marijuana Corp
18.20.1. Company Details
18.20.2. Company Overview
18.20.3. Product Offerings
18.20.4. Key Developments
18.20.5. Financial Analysis
18.20.6. SWOT Analysis
18.20.7. Business Strategies
18.21. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.